Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Honghui Zhou

Showing results (131-140 of 143) with videos related to

Pageof 15
Sort By:
The AAPS Journal|June 2, 2011
AAPS workshop report: strategies to address therapeutic protein-drug interactions during clinical developmentSandhya Girish, Steven W Martin, Mark C Peterson, et al.
Clinical and Translational Science|June 26, 2020
Early M-Protein Dynamics Predicts Progression-Free Survival in Patients With Relapsed/Refractory Multiple MyelomaXiaoyu Yan, Xu Steven Xu, Katja C Weisel, et al.
ACS Applied Materials & Interfaces|June 14, 2016
Two-Dimensional Layered Oxide Structures Tailored by Self-Assembled Layer Stacking via Interfacial StrainWenrui Zhang, Mingtao Li, Aiping Chen, et al.
Advances in Therapy|February 21, 2020
Split First Dose Administration of Intravenous Daratumumab for the Treatment of Multiple Myeloma (MM): Clinical and Population Pharmacokinetic AnalysesXu Steven Xu, Philippe Moreau, Saad Z Usmani, et al.
Journal of Clinical Pharmacology|November 4, 2020
Exposure-Response and Population Pharmacokinetic Analyses of a Novel Subcutaneous Formulation of Daratumumab Administered to Multiple Myeloma PatientsMan Melody Luo, Saad Z Usmani, Maria-Victoria Mateos, et al.
Journal of Clinical Pharmacology|October 28, 2021
Population Pharmacokinetics and Exposure-Response Modeling of Daratumumab Subcutaneous Administration in Patients With Light-Chain AmyloidosisMan Melody Luo, Peijuan Penny Zhu, Ivo Nnane, et al.
Clinical Pharmacology in Drug Development|May 1, 2023
A Phase 1 First-in-Human Pharmacokinetic and Pharmacodynamic Study of JNJ-64264681, a Covalent Inhibitor of Bruton's Tyrosine KinaseJocelyn H Leu, Xin Miao, Kevin Shalayda, et al.
Journal of Clinical Pharmacology|February 27, 2007
Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritisHonghui Zhou, Haishan Jang, Roy M Fleischmann, et al.
Journal of Affective Disorders|September 3, 2024
Psychosocial functioning and its influencing factors in patients with depression post-remission: Implications for assessment and interventionsHao Yang, Mengjiao Wu, Wenyan Huang, et al.
The AAPS Journal|March 15, 2025
Therapeutic Drug Monitoring of Biologics: Current Practice, Challenges and Opportunities - a Workshop ReportSophie Shubow, Michele Gunsior, Amy Rosenberg, et al.
Pageof 15

Showing results (131-140 of 143) with videos related to

Sort By:
Pageof 15
The AAPS Journal|June 2, 2011
AAPS workshop report: strategies to address therapeutic protein-drug interactions during clinical developmentSandhya Girish, Steven W Martin, Mark C Peterson, et al.
Clinical and Translational Science|June 26, 2020
Early M-Protein Dynamics Predicts Progression-Free Survival in Patients With Relapsed/Refractory Multiple MyelomaXiaoyu Yan, Xu Steven Xu, Katja C Weisel, et al.
ACS Applied Materials & Interfaces|June 14, 2016
Two-Dimensional Layered Oxide Structures Tailored by Self-Assembled Layer Stacking via Interfacial StrainWenrui Zhang, Mingtao Li, Aiping Chen, et al.
Advances in Therapy|February 21, 2020
Split First Dose Administration of Intravenous Daratumumab for the Treatment of Multiple Myeloma (MM): Clinical and Population Pharmacokinetic AnalysesXu Steven Xu, Philippe Moreau, Saad Z Usmani, et al.
Journal of Clinical Pharmacology|November 4, 2020
Exposure-Response and Population Pharmacokinetic Analyses of a Novel Subcutaneous Formulation of Daratumumab Administered to Multiple Myeloma PatientsMan Melody Luo, Saad Z Usmani, Maria-Victoria Mateos, et al.
Journal of Clinical Pharmacology|October 28, 2021
Population Pharmacokinetics and Exposure-Response Modeling of Daratumumab Subcutaneous Administration in Patients With Light-Chain AmyloidosisMan Melody Luo, Peijuan Penny Zhu, Ivo Nnane, et al.
Clinical Pharmacology in Drug Development|May 1, 2023
A Phase 1 First-in-Human Pharmacokinetic and Pharmacodynamic Study of JNJ-64264681, a Covalent Inhibitor of Bruton's Tyrosine KinaseJocelyn H Leu, Xin Miao, Kevin Shalayda, et al.
Journal of Clinical Pharmacology|February 27, 2007
Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritisHonghui Zhou, Haishan Jang, Roy M Fleischmann, et al.
Journal of Affective Disorders|September 3, 2024
Psychosocial functioning and its influencing factors in patients with depression post-remission: Implications for assessment and interventionsHao Yang, Mengjiao Wu, Wenyan Huang, et al.
The AAPS Journal|March 15, 2025
Therapeutic Drug Monitoring of Biologics: Current Practice, Challenges and Opportunities - a Workshop ReportSophie Shubow, Michele Gunsior, Amy Rosenberg, et al.
Pageof 15